NATCO Pharma informs about disclosure

09 Nov 2022 Evaluate

NATCO Pharma has informed that it enclosed the disclosure under Regulation 30 of SEBI (LODR) Regulations 2015 regarding ‘NATCO Announces Launch of First Generic Version of Pomalyst® (Pomalidomide) Capsules in the Australian Market’.

The above information is a part of company’s filings submitted to BSE.

Natco Pharma Share Price

1002.20 -17.15 (-1.68%)
09-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1807.60
Dr. Reddys Lab 1286.40
Cipla 1325.15
Zydus Lifesciences 908.65
Lupin 2301.70
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×